We're moving to rndsystems.com. Come with us!

After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.

RPE

Using RPE65 as a tool to investigate ocular gene therapies

While not life threatening, blindness and retinal disease are profoundly debilitating and greatly affect quality of life.  Understandably, gene therapy has been subject to controversy given it’s potential effects on the rest of our cellular processes.  However, a genetically diseased eye being an isolated organ quickly becomes a promising prospect for such therapies.  Specifically, RPE antibodies are powerful diagnostic tools to test the viability of these clinical treatments.